CJC-1295 DAC 5mg Lyophilised: Research Profile and Laboratory Specifications

Assuming that all synthetic growth hormone-releasing analogues behave identically in laboratory assays overlooks a fundamental chemical reality: the covalent Drug Affinity Complex completely transforms peptide half-life and target interactions. If you’ve ever dealt with inconsistent assay results, you already know how difficult it is to confirm whether the bioconjugation moiety is fully intact or if a batch has been mistakenly substituted with non-conjugated modified GRF (1-29). Working with CJC-1295 DAC 5mg lyophilised solid demands complete certainty regarding structural integrity, analytical purity, and proper handling mechanics.

This technical guide examines the biochemical profile, standardised laboratory reconstitution protocols, analytical purity standards, and in vitro storage stability data for this compound. Ahead, we detail the exact high-performance liquid chromatography and mass spectrometry benchmarks required to eliminate experimental ambiguity and preserve procedural control.

Biochemical Profile and Structure of CJC-1295 DAC 5mg Lyophilised Solid

The synthetic compound designated as CJC-1295 is a 30-amino-acid tetrasubstituted peptide analogue of growth hormone-releasing hormone (GHRH). In research settings, CJC-1295 with Drug Affinity Complex undergoes spontaneous covalent bioconjugation to endogenous circulating albumin via a stable maleimide-thiol linkage. This mechanism fundamentally distinguishes the compound from modified GRF (1-29), which lacks the functional bioconjugating linker and therefore remains unprotected in systemic fluid models.

High-grade preparations of CJC-1295 DAC 5mg lyophilised material appear as a uniform, dense white cake. During secondary drying, vials undergo inert nitrogen backfilling before mechanical sealing with chlorobutyl rubber stoppers. This protective barrier prevents moisture adsorption and oxidative cleavage across vulnerable peptide bonds during cold-chain distribution.

Tetrasubstituted Molecular Architecture and Enzymatic Resistance

Native GHRH degrades rapidly through dipeptidyl peptidase-4 (DPP-4) cleavage. To eliminate this susceptibility, researchers substituted key residues across the sequence:

• Position 2: D-Alanine replaces L-alanine, providing steric hindrance against DPP-4 cleavage.
• Position 8: L-Glutamine replaces L-asparagine to reduce spontaneous deamidation.
• Position 15: L-Alanine replaces L-glycine, improving structural alpha-helix stability.
• Position 27: L-Leucine replaces L-methionine, preventing oxidative degradation at elevated temperatures.

The resulting chemical structure corresponds to the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ with an exact theoretical molecular weight of approximately 3647.28 g/mol for the conjugated complex.

The Role of the Drug Affinity Complex (DAC)

The bioconjugation mechanics rely entirely on the C-terminal addition: a lysine linker functionalised with maleimidopropionic acid (MPA). Upon contact with biological fluids or albumin-containing media, the maleimide group reacts selectively with the unpaired cysteine-34 thiol on serum albumin. This bond shields the peptide backbone from renal clearance and neutral endopeptidase digestion.

Preclinical assays demonstrate that albumin binding shifts biological half-life from roughly 30 minutes (observed in unmodified analogues) to 5.8 to 8.1 days in mammalian test systems. For a detailed breakdown of clearance kinetics and degradation pathways across secretagogues, examine the comparative stability data outlined in peptide half life explained.

CJC-1295 with DAC vs. Modified GRF 1-29: Comparative Research Specifications

Conflating CJC-1295 with Drug Affinity Complex and Modified GRF 1-29 compromises experimental validity. While both compounds share a core 29-amino-acid tetrasubstituted backbone derived from human GHRH, their pharmacokinetic profiles, binding properties, and kinetic clearance rates diverge entirely. Laboratory teams must establish clear analytical frameworks to distinguish these peptides prior to running in vitro cell culture or microdialysis protocols.

Molecular Weight and Mass Spectrometry Discrepancies

Mass spectrometry readily resolves ambiguity between these variants. Unconjugated Modified GRF presents an average monoisotopic mass of approximately 3367 g/mol. In contrast, the addition of the lysine residue and maleimidopropionic acid moiety increases the molecular mass of CJC-1295 DAC 5mg lyophilised material to approximately 3647.28 g/mol.

Analytical technicians evaluating spectral data must identify this clear 280 Da difference. Catalogue reagents missing this mass shift represent non-conjugated peptide. If your experimental models require confirmed analytical purity across these analogues, you can verify batch specifications in the 24hour Peptides COA library before reconstituting solid samples.

Signalling Dynamics in Pituitary Receptor Models

Receptor occupancy kinetics directly shape cell behaviour. Modified GRF mimics endogenous GHRH pulses, triggering sharp, transient spikes in intracellular cyclic adenosine monophosphate (cAMP) accumulation before rapid enzymatic degradation resets the system. Conversely, albumin-bound CJC-1295 DAC provides sustained GHRH receptor occupancy.

Peer-reviewed investigations into CJC-1295 and GH/IGF-1 Axis Activation show that prolonged receptor engagement creates sustained downstream biological signalling rather than isolated episodic spikes. Because continuous stimulation alters desensitisation rates and downregulates specific surface receptors over extended durations, choice of compound dictates whether sampling protocols require hourly or multi-day collection intervals.

Laboratory Reconstitution Protocols and Reagent Calculations for 5mg Vials

Working with synthetic bioconjugates requires strict aseptic discipline to preserve fragile secondary structures. Before introducing any liquid volume into a vial containing CJC-1295 DAC 5mg lyophilised solid, technicians must carry out thermodynamic equilibration. Moving a refrigerated or frozen vial straight into solvent hydration causes rapid atmospheric moisture condensation inside the septum neck and creates thermal gradients that disrupt consistent dissolution.

Equally important is managing internal vial pressure. Because standard manufacturing involves low-pressure nitrogen sealing, an unmitigated vacuum can pull diluent into the glass violently. This mechanical impact shears polypeptide chains. Allowing solvent to trickle slowly along the internal glass perimeter avoids this force entirely.

Step-by-Step Aseptic Reconstitution Technique

Executing reconstitution under a class II laminar flow hood ensures procedural consistency and prevents contamination across successive assay runs:

• Equilibrate: Allow the sealed vial to stand at controlled room temperature (20°C to 25°C) for 20 to 30 minutes.
• Sanitise: Swab the chlorobutyl rubber stopper with a sterile 70% isopropyl alcohol wipe and let the surface air-dry completely.
• Introduce Diluent: Draw your measured volume of bacteriostatic water 10ml. Angle the needle tip against the inner glass wall so the liquid runs down gently without striking the lyophilised cake directly.
• Dissolve: Slowly roll the vial between your palms. Never shake, agitate, or vortex the solution, as high mechanical shear induces peptide aggregation and precipitation.
• Inspect: Examine the reconstituted fluid under direct light. The liquid must appear completely clear and free of visible flocculent, suspended particulates, or persistent cloudiness.

Molarity and Concentration Standards for a 5mg Matrix

Accurate in vitro dispensing relies on precise volumetric ratios. Reconstituting a 5mg cake with standard laboratory diluent volumes yields the following concentrations:

• 1.0 ml Addition: Produces a final working concentration of 5.0 mg/ml (5,000 mcg/ml).
• 2.0 ml Addition: Yields a stock concentration of 2.5 mg/ml (2,500 mcg/ml).
• 2.5 ml Addition: Results in an easily divisible concentration of 2.0 mg/ml (2,000 mcg/ml).

Once dissolved, divide the stock solution immediately into sterile, low-binding polypropylene microcentrifuge tubes according to your experimental volumes. Aliquoting prevents destructive repeat freeze-thaw cycles. For expanded calculation formulas and solvent compatibility profiles, consult the comprehensive peptide reconstitution guide.

Analytical Purity Verification: Assessing HPLC and Mass Spectrometry on COAs

Analytical verification confirms that experimental reagents meet the strict criteria demanded by biochemical research. When sourcing CJC-1295 DAC 5mg lyophilised material, relying on generalized catalogue statements introduces unquantified variables into cell culture assays. Establishing research-grade status requires laboratory professionals to evaluate raw chromatographic and spectrometric data directly, verifying target mass, secondary structure retention, and the absence of residual synthesis reagents.

A complete Certificate of Analysis (COA) must detail three core parameters: chromatographic purity via High-Performance Liquid Chromatography (HPLC), mass confirmation using Electrospray Ionisation Mass Spectrometry (ESI-MS), and quantification of gross counter-ions. Acceptable research standards require total purity levels equal to or exceeding 98%, net peptide content above 80%, and residual trifluoroacetic acid (TFA) controlled to minimal trace levels to prevent cellular toxicity.

Interpreting High-Performance Liquid Chromatography (HPLC) Data

Reversed-phase HPLC on a standard C18 analytical column separates peptides based on hydrophobic interactions. When reviewing the primary chromatogram, look for a single, sharp, symmetrical elution peak corresponding to the intact conjugated molecule. Asymmetrical peaks, fronting, or split peaks indicate co-eluting impurities, such as truncated synthesis sequences or oxidised methionine-substitute variants.

Calculate purity by verifying that the area-under-the-curve (AUC) of the target analyte integrates to at least 98% of total detected peak area at 214 nm or 220 nm. Trace secondary peaks eluting earlier generally represent shorter deletion fragments, whereas trailing peaks often stem from incomplete deprotection during solid-phase peptide synthesis.

Independent Documentation and Batch Traceability

Mass spectrometry provides unambiguous identity confirmation. ESI-MS spectra should clearly resolve the theoretical monoisotopic mass of the complete complex (approx. 3647.28 g/mol) alongside typical multiple-charge states ([M+3H]³⁺, [M+4H]⁴⁺). A mass readout terminating near 3367 g/mol signals a non-conjugated analogue missing the bioconjugation arm, while isolated low-mass spikes reveal unreacted, free maleimidopropionic acid linker molecules.

Always verify that batch and lot numbers stamped on the physical vial label match those on testing documentation. You can review independent, third-party analytical reports across recent production batches by visiting the public 24hour Peptides COA library before introducing novel lots into active protocols. If you require verified research compounds with fully accessible analytical traceability, explore the full catalogue of verified materials in our shop.

Laboratory Storage Conditions, Thermal Stability, and Handling Guidelines

Thermal stability directly dictates experimental longevity. When peptides experience fluctuating ambient temperatures, spontaneous peptide bond hydrolysis and covalent cleavage accelerate dramatically. Preserving intact CJC-1295 DAC 5mg lyophilised solid requires disciplined cold-chain management from delivery through to assay completion. In addition, bench personnel must maintain standard chemical hygiene by wearing nitrile gloves, protective eyewear, and lab coats to mitigate aerosolisation risks and prevent cross-contamination during handling.

Lyophilised Solid versus Reconstituted Solution Storage

Unopened vials containing the lyophilised cake exhibit exceptional thermodynamic stability when stored at -20°C for up to 24 months. For multi-year storage, -80°C provides maximal protection against slow chemical degradation. Place vials inside airtight secondary containers with indicating silica gel packets; this barrier stops moisture from permeating the chlorobutyl septum during extended freezer storage.

Once dissolved in diluent, the compound’s stability profile narrows considerably. Reconstituted aqueous solutions must be stored at 2°C to 8°C and consumed in experimental models within 21 to 28 days. Keep liquid vials shielded from direct ambient light, as ultraviolet radiation triggers photolytic degradation. Avoid repeated freeze-thaw cycles under all circumstances. Ice-crystal formation exerts physical shear forces on the peptide backbone, inducing secondary structure denaturation and irreversible aggregation.

Sourcing Research-Grade Compounds in the UK

Securing chemically verified reagents forms the baseline of reproducible in vitro research. When procuring CJC-1295 DAC 5mg lyophilised vials, scientific institutions must select dependable domestic suppliers that adhere to verified analytical standards. Sourcing through UK distributors prevents protracted international transit times that could otherwise compromise temperature-sensitive materials.

Research facilities can procure batch-tested compounds directly through the 24hour Peptides research peptides UK catalogue. Under domestic legal frameworks, including the Human Medicines Regulations 2012, CJC-1295 DAC is supplied strictly for in vitro and laboratory scientific investigation. Maintaining institutional alignment with chemical handling guidelines ensures procedural safety and reproducible experimental assays across every project.

Advancing Reagent Integrity in Downstream Research

Maintaining strict control over growth hormone-releasing assays begins with verified peptide chemistry. Confirming that your CJC-1295 DAC 5mg lyophilised material possesses an intact maleimide linker ensures continuous receptor models behave predictably and mirror documented clearance kinetics. When paired with gentle, wall-directed reconstitution techniques and disciplined cold-chain preservation, your laboratory protects the peptide backbone against shear stress and premature hydrolytic degradation.

Analytical transparency remains the foundation of reproducible in vitro science. 24hour Peptides supplies high-purity lyophilised solids engineered for experimental stability, strictly aligned with UK research standards and supported by prompt domestic dispatch. Every compound is independently tested, with batch-specific Certificates of Analysis available online to verify chromatographic purity and exact molecular mass before you initiate sensitive benchwork. To support your experimental workflows with documented reagent quality and dependable domestic distribution, visit 24hour Peptides for your laboratory research requirements.

Frequently Asked Questions

What is the exact distinction between CJC-1295 DAC and CJC-1295 No DAC in laboratory research?

The primary distinction lies in the addition of the Drug Affinity Complex linker, consisting of maleimidopropionic acid attached via a lysine linker. Without this complex, the peptide is Modified GRF (1-29), which exhibits a rapid half-life of roughly 30 minutes in biological fluids. In contrast, CJC-1295 with DAC binds endogenous albumin, sustaining its half-life for approximately 5.8 to 8.1 days. This variance completely alters receptor kinetics and sampling schedules in experimental settings.

How should a 5mg vial of CJC-1295 DAC lyophilised solid be stored prior to reconstitution?

Unopened vials of CJC-1295 DAC 5mg lyophilised solid should be stored at -20°C for routine research schedules up to 24 months, or at -80°C for extended multi-year preservation. Vials must remain protected from light exposure and sealed in moisture-controlled containers containing silica desiccant. Preventing humidity ingress through the chlorobutyl stopper safeguards the freeze-dried cake against moisture-mediated peptide hydrolysis and preserves chemical stability before reconstitution.

Which laboratory diluents are recommended for dissolving CJC-1295 DAC for scientific assays?

Laboratory-grade bacteriostatic water containing 0.9% benzyl alcohol is the standard diluent for multi-use experimental protocols. It prevents microbial proliferation over consecutive sample draws. For single-use or in vitro cell culture systems where benzyl alcohol might interfere with cellular viability assays, researchers utilise sterile 0.9% sodium chloride solution or sterile water for injection, proceeding with testing immediately post-hydration.

What analytical methods are required to verify the purity and identity of CJC-1295 DAC?

Purity verification requires reversed-phase High-Performance Liquid Chromatography (HPLC) to establish a chromatographic purity benchmark equal to or exceeding 98%. In parallel, Electrospray Ionisation Mass Spectrometry (ESI-MS) confirms molecular identity, resolving the expected molecular weight of approximately 3647.28 g/mol. Together, these analytical techniques detect unwanted synthesis truncated fragments, deamidation artefacts, and unreacted linker molecules in the solid matrix.

How long does reconstituted CJC-1295 DAC remain chemically stable at refrigerated temperatures?

Once reconstituted, aqueous CJC-1295 DAC solutions should be held between 2°C and 8°C and utilised within 21 to 28 days. Liquid peptides experience accelerated hydrolytic cleavage relative to dry cakes. To maintain maximal structural integrity, researchers should shield the reconstituted solution from light and avoid repeat freeze-thaw cycles by aliquoting working volumes into single-use polypropylene tubes immediately after dissolution.

Is CJC-1295 DAC 5mg approved for clinical or human administration in the UK?

No, CJC-1295 DAC is not licensed as a medicine or approved for clinical or human administration in the United Kingdom. Under the Human Medicines Regulations 2012, its supply for human use or consumption is strictly prohibited. Sourcing CJC-1295 DAC 5mg lyophilised solid through 24hour Peptides is intended solely for scientific research, in vitro experimentation, and qualified laboratory analysis.

What is the role of the Drug Affinity Complex (DAC) in peptide research models?

The Drug Affinity Complex provides a covalent conjugation mechanism that protects the synthetic peptide from rapid renal clearance and enzymatic degradation. By selectively reacting with the free cysteine-34 thiol on circulating serum albumin, the DAC moiety creates a stable macro-complex. In scientific investigative models, this bioconjugation provides sustained pituitary receptor engagement, allowing researchers to evaluate continuous GHRH receptor signalling dynamics rather than transient episodic peaks.